China’s CSPC Pharmaceutical Group will begin human trials of an mRNA vaccine it developed to treat certain cancers after winning regulatory approval.
“The product is the world’s first mRNA-LNP-based cell therapy product approved for clinical trials,” the company said.
The treatment uses the same mRNA system pioneered by BioNTech/Pfizer and involves inserting fragments of mRNA into lipid nanoparticles that can enter cells to change their genetic code.
The vaccine was cleared for human trials in China for treating myeloma cancers, which affect white blood cells. The company says it has potential for treating autoimmune diseases, including lupus.
CSPC’s Hong Kong shares rose 3.1 per cent on Wednesday, while the city’s broader Hang Seng index was flat.
Read the full article here